Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): William McIntyre Added: 1 year ago
EHRA 24 - Investigator, Dr William McIntyre (Population Health Research Institute, CA) joins us to discuss the findings from a substudy of ARTESiA (NCT01938248).ARTESiA was a randomized, parallel assignment clinical trial which aimed to assess if apixaban could reduce the risk of ischemic stroke and systemic embolism in patients with subclinical atrial fibrillation (AF) and additional risk… View more
Author(s): Thorsten Hanke Added: 8 months ago
First presented at ESC 2024, this on-demand programme sees Prof Gregory Lip(University of Liverpool, UK) lead a faculty comprisingProf Elena Arbelo (University of Barcelona, ES), ProfThorsten Hanke(Asklepios Klinikum Harburg, DE) andProf Richard Whitlock(McMaster University, CA) review the application of the latest AF guidance in a clinical setting.This case-based programme explores the… View more
Author(s): Gerhard Hindricks , Faizel Osman , Keitaro Senoo , et al Added: 1 year ago
This video series page covers content associated with Atrial Fibrillation.AFib is associated with a 5x greater risk of stroke, however with effective treatment, the risk of stroke can be reduced.¹ The lifetime risk for AFib is 1 in 3 individuals² and it often occurs with hypertension. Early detection is key, to allow for prompt and satisfactory disease management to not only control symptoms but… View more
Author(s): Else Sandset , Jesse Dawson , Urs Fischer , et al Added: 1 year ago
Dr Else Sandset (Oslo University Hospital, NO) is joined by Prof Jesse Dawson (University of Glasgow, GB), Dr Urs Fischer (University Hospital Basel, CH) and Dr Masatoshi Koga (National Cerebral and Cardiovascular Center, JP) to discuss the findings from their recent paper on "Early versus Later Anticoagulation for Stroke with Atrial Fibrillation" published in the New England Journal of Medicine… View more
Start date: Sep 01, 2024 End date: Sep 01, 2024
Radcliffe Medical Education is hosting a symposium entitled 'AF Stroke Prevention: Applying New Guidance in the Real World' at 15:15 UTC+1 on Sunday 1 September 2024 in Dublin Room atESC 2024, ExCel Centre, London, UK.Add to your calendar.OverviewProf Gregory Lip(University of Liverpool, Liverpool, UK) will lead a faculty comprisingProf Elena Arbelo (University of Barcelona, ES), ProfThorsten… View more
Author(s): Naima Maqsood , Jeff Healey Added: 1 year ago
AHA 2023 — Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews investigator, Dr Jeff Healey (McMaster University, CA) to outline the findings from a phase 4 trial of apixaban to reduce thromboembolism in patients with subclinical atrial fibrillation (AF).ARTESiA (NCT01938248) aims to determine if apixaban in combination with aspirin can reduce the instance of… View more
Author(s): Kengo Kusano Added: 1 year ago
ACC.24 — We are joined by Dr Kengo Kusano (National Cerebral and Cardiovascular Center, JP) to discuss the findings from the Embo-Abl Study.Embo-Abl is a multicenter prospective randomized study which aims to compare the incidence of periprocedural cerebral embolisms caused by catheter ablation of atrial fibrillation (AF) between cryoballoon and radiofrequency ablation. 230 patients with AF from… View more
Author(s): Emma Sandgren Added: 1 month ago
EHRA 2025 - Outcomes from model screening for atrial fibrillation (AF) show the combination of a risk prediction model and long-term electrocardiogram (ECG) monitoring is superior to standard of care in detecting new cases of AF in a high-risk population aged 65 years or older. In the risk prediction model arm, the incidence of AF after six months was significantly higher than the incidence in… View more
Author(s): Renato D Lopes Added: 8 months ago
ESC Congress 24 — AF screening with a wearable ECG device increases diagnosis by over 50% but did not significantly reduce hospitalisation rates for stroke.We are joined onsite at ESC Congress 2024 by Dr Renato Lopes (Duke University Medical Center, NC) to discuss the findings from the GUARD-AF Trial (NCT04126486, Bristol-Myers Squibb), which was designed to determine if screening for undiagnosed… View more